Capsida Biotherapeutics has suspended its phase I/II clinical trial of CAP-002 gene therapy for STXBP1 encephalopathy following the death of the first enrolled pediatric patient. The trial, which began enrolling in July, focuses on a rare neurodevelopmental disorder with limited treatment options. The company and investigators are investigating the cause of death to determine implications for the therapy’s safety and future development.